Metastatic Colorectal Cancer Epidemiology Research Report 2022 – Forecast 2032 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Metastatic Colorectal Cancer – Epidemiology Forecast – 2032” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This Metastatic Colorectal Cancer (mCRC)- Epidemiology Forecast-2032 report delivers an in-depth understanding of the mCRC, historical and forecasted epidemiology as well as the mCRC trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

Diagnosis

The first and foremost step in evaluating, Patients can present with a wide range of signs and symptoms such as occult or overt rectal bleeding, change in bowel habits, anemia, or abdominal pain. However, CRC is largely an asymptomatic disease until it reaches an advanced stage. By contrast, rectal bleeding is a common symptom of both benign and malignant causes.

Therefore additional risk factors might be needed to help identify those people who should undergo further investigation by colonoscopy. New-onset rectal bleeding should generally prompt colonoscopy in individuals aged 45 years or older.

In younger patients, additional factors are used to identify those at highest risk for CRC (e.g., having a family history of CRC, change in bowel habits, unexplained weight loss, and blood mixed with the stool as opposed to blood on the surface of the stool).

For diagnosing CRC, colonoscopy is the method of choice. Colonoscopy identification of advanced lesions is relatively straightforward, but early CRCs might appear as very subtle mucosal lesions (e.g., an innocuous flat laterally spreading polyp), imaging, laboratory, pathology, biopsy, blood test, tumor based tests, etc.

Metastatic Colorectal Cancer (mCRC) Epidemiology

The epidemiology section provides insights about the historical and current mCRC patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Topics Covered:

1. Key Insights

2. Report Introduction

3. Metastatic Colorectal Cancer (mCRC) Market Overview at a Glance

3.1. Market Share (%) Distribution of mCRC in 2019

3.2. Market Share (%) Distribution of mCRC in 2032

4. Executive Summary of Metastatic Colorectal Cancer (mCRC)

4.1. Key Events

5. Epidemiology and Market Methodology

6. Disease Background and Overview

6.1. Introduction

6.2. Causes

6.3. Symptoms

6.4. CRC Staging

6.5. Risk Factors of CRC

6.6. Molecular Subtypes of CRC

6.7. Mechanisms of Metastasis in CRC

6.8. Drug Resistance in mCRC

6.9. Clinical Presentation of mCRC

6.10. Unusual Sites of Metastasis in CRC

6.10.1. Uterine Metastasis

6.10.2. Penile Metastasis

6.10.3. Scrotal Metastasis

6.10.4. Prostatic Metastasis

6.10.5. Bladder Metastasis

6.10.6. Peritoneal Pseudomyxoma

6.10.7. Abdominal Wall Metastasis

6.10.8. Bone Metastasis

6.10.9. Carcinomatous Lymphangitis

6.10.10. Adenopathies

6.10.11. Pancreatic Metastasis

6.11. Biomarkers in mCRC

6.11.1. Prognostic Biomarkers

6.11.2. Patient-Related Factors

6.11.3. Tumor-related Factors

6.11.4. Predictive Biomarkers

6.11.5. Markers to Predict 5-FU Response and Toxicity

6.11.6. Predicting Response to EGFR Therapy

6.11.7. Predicting Response to VEGF Inhibitors

6.11.8. Technology-Facilitated Biomarkers

6.12. Diagnosis

6.12.1. Clinical symptoms

6.12.2. Endoscopy

6.12.3. Imaging

6.12.4. Laboratory

6.12.5. Pathology

6.12.6. Biopsy

6.12.7. Molecular Testing of the Tumor

6.12.8. Blood Tests

6.12.9. Tumor-based Tests

6.12.10. Diagnosis of colorectal liver metastasis

7. Recognized Establishments

8. Treatment of Metastatic Colorectal Cancer (mCRC)

8.1. Initial/First-line Treatment of mCRC

8.2. Second and Third-line Treatment of mCRC

8.3. Therapies using medication

8.4. Surgery

8.5. Adjuvant therapy

8.6. Follow-up

8.7. Palliation

8.8. Maintenance Therapy

8.9. Treatment of Colon Cancer That Has Metastasized to a Single Site

9. Treatment of Patients with Late-stage Colorectal Cancer: ASCO Resource-Stratified Guideline (2020)

10. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer (2016)

10.1. Recommendations

10.1.1. Recommendation 1: Tissue handling

10.1.2. Recommendation 2: A selection of specimens for biomarker testing

10.1.3. Recommendation 3: Tissue selection

10.1.4. Recommendation 4: RAS testing

10.1.5. Recommendation 5: BRAF testing

10.1.6. Recommendation 6: MSI testing

10.1.7. Recommendation 7: Biomarkers of chemotherapy sensitivity and toxicity

10.1.8. Recommendation 8: Emerging biomarkers not recommended for routine patient management outside of a clinical trial setting

10.1.9. Recommendation 9: Emerging technologies

10.1.10. Recommendation 10: OMD

10.1.11. Recommendation 11: Imaging in the identification and management of disease

10.1.12. Recommendation 12: Perioperative treatment

10.1.13. Recommendation 13: Conversion therapy

10.1.14. Recommendation 14: Ablative techniques

10.1.15. Recommendation 15: Local ablation techniques

10.1.16. Recommendation 16: Embolization

10.1.17. Recommendation 17: Cytoreductive surgery and HIPEC

10.1.18. Recommendation 18: First-line systemic therapy combinations according to the targeted agent used

10.1.19. Recommendation 19: Maintenance therapy

10.1.20. Recommendation 20: Second-line combinations with targeted agents

10.1.21. Recommendation 21: Third-line therapy

10.2. Consensus recommendations on the use of cytotoxics and biologicals in the first- and subsequent-line treatment of patients with mCRC

10.2.1. Consensus recommendation for patients where cytoreduction with ‘conversion’ and/or the integration of local ablative treatment is the goal

10.2.2. Consensus recommendation for patients where cytoreduction is needed because of aggressive biology and/or risk of developing or existing severe symptoms

10.2.3. Consensus recommendation for patients where disease control is the goal

11. National Institute for Health and Care Excellence (NICE) Guidelines: Colorectal Cancer (2020)

11.1. Management of metastatic disease

11.1.1. People with asymptomatic primary tumor

11.1.2. People with mCRC in the liver

11.1.3. People with metastatic colorectal cancer in the lung

11.1.4. People with metastatic colorectal cancer in the peritoneum

11.2. Ongoing care and support

11.2.1. Follow-up for detection of local recurrence and distant metastases

12. Management of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM) (2016)

12.1. Metastatic CRC Treatment Recommendations

12.1.1. Evaluation of elderly patients

12.1.2. Surgery for advanced disease

12.1.3. Locoregional treatments

13. Treatment guidelines of metastatic colorectal cancer in older patients from the French Society of Geriatric Oncology (SoFOG)

13.1. Recommendations on palliative chemotherapy indication for older patients with mCRC

13.2. Recommendations for cytotoxic chemotherapy in older patients:

13.3. Anti-angiogenic recommendations for older:

13.4. Recommendations for anti-EGFR, regorafenib and trifluridinetipiracil in older patients

14. Spanish Society of Medical Oncology (SEOM) clinical guidelines for diagnosis and treatment of metastatic colorectal cancer (2018)

15. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines for the treatment of colorectal cancer- 2019

15.1. Treatment strategies for Stage IV CRC

15.2. Treatment strategies for hematogenous metastases

15.2.1. Treatment strategies for liver metastases

15.2.2. Treatment strategies for brain metastases

15.2.3. Treatment strategies for hematogenous metastases to other organs

16. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Colon and Rectal Cancer (2021)

17. Epidemiology and Patient Population

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/ht15o9

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900